Loading
Tracheal and Airway Disorders · Journal article
Psycho-oncologie · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This scoping review characterizes HFNC as a potentially supportive noninvasive respiratory modality in advanced cancer that may reduce dyspnea and preserve communication and oral intake. No quantitative synthesis, effect sizes, or controlled comparisons are presented; the conclusions rest on qualitative synthesis of unspecified literature and remain exploratory.
Scoping review. Literature on HFNC in advanced cancer; specific inclusion/exclusion criteria not stated. Intervention: High-flow nasal cannula (HFNC) oxygen therapy. Compared with: Other respiratory support modalities, including noninvasive ventilation (NIV).
HFNC may reduce dyspnea while preserving ability to communicate and maintain oral intake during terminal phase HFNC may offer advantages in tolerability, comfort, and psychological acceptability compared with noninvasive ventilation (NIV) HFNC may support patient autonomy and shared decision-making in end-of-life care and advance care planning
HFNC may offer advantages in tolerability, comfort, and psychological acceptability compared with noninvasive ventilation (NIV)
Clinicians considering respiratory support in advanced cancer may view HFNC as a potentially less burdensome alternative to NIV that preserves communication; however, the evidence remains qualitative and lacks quantified benefit or harm, so decisions require individual assessment and shared decision-making.
A scoping review synthesizing disparate evidence on HFNC in advanced cancer with qualitative conclusions about potential benefits, but no quantitative outcomes, controlled comparisons, or meta-analysis to establish effect size.
As stated by the source record.
Clinicians considering respiratory support in advanced cancer may view HFNC as a potentially less burdensome alternative to NIV that preserves communication; however, the evidence remains qualitative and lacks quantified benefit or harm, so decisions require individual assessment and shared decision-making.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
High-flow nasal cannula (HFNC) oxygen therapy has received increasing attention as a noninvasive respiratory support modality for patients with advanced cancer. This scoping review examines the clinical application of HFNC in advanced cancer complicated by respiratory failure, with a focus on its potential contributions to symptom relief, quality of life (QoL), psychological well-being, and family-centered decision-making. By synthesizing current clinical evidence, this scoping review suggests that HFNC may reduce dyspnea while helping preserve patients’ ability to communicate and maintain oral intake during the terminal phase, thereby supporting overall QoL. Compared with other respiratory support modalities, such as noninvasive ventilation (NIV), HFNC may offer advantages in tolerability, comfort, and psychological acceptability. However, challenges remain, including ethical dilemmas, resource allocation, and decisions regarding treatment withdrawal. Overall, HFNC may have a supportive role in end-of-life care and advance care planning by supporting patient autonomy and shared decision-making among patients, families, and healthcare professionals.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.